Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination of Ibrutinib and As2O3 in the Treatment of CLL
NCT02757040Phase 3Unknown
- Sponsor
- Peking University People's Hospital
- Start
- Dec 2016
- Primary completion
- Dec 2017
- Modality
- DNA Intercalators/Alkylators
01
Overview
Phase 3, randomised trial of arsenic trioxide in chronic lymphocytic leukemia (CLL) (2 arms), sponsored by Peking University People's Hospital. Primary endpoint: Overall Response Rate at 2 years. Status: unknown.
02
Drugs
arsenic trioxide
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02757040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02757040.